Effects of mithramycin on calcium metabolism and bone in dogs.

Vet Pathol

Department of Veterinary Pathobiology, Ohio State University, Columbus.

Published: May 1992

Mithramycin (0.1 mg/kg) was administered intravenously to eight Beagle dogs on days 0 and 7 to determine its effects on calcium and phosphorus metabolism, serum parathyroid hormone concentration, osteoclastic bone resorption, and serum biochemical and hematologic parameters. Ionized calcium concentration was paradoxically increased on day 1 and decreased on day 8 in association with an increased serum parathyroid hormone concentration. Serum phosphorus concentration was decreased on days 1 and 2. Osteoclastic bone resorption in iliac cancellous bone was significantly decreased on day 8. There were mild increases in serum alkaline phosphatase (days 1, 2, 4, 8, 9), aspartate aminotransferase (day 9), and gammaglutamyl transpeptidase (days 7, 9) activities. Platelet numbers were increased on days 7 through 13, and packed red blood cell volumes were mildly decreased. This investigation demonstrates that two doses of mithramycin can be administered safely to dogs and may inhibit bone resorption in diseases associated with increased osteoclastic bone resorption, such as humoral hypercalcemia of malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1177/030098589202900306DOI Listing

Publication Analysis

Top Keywords

bone resorption
16
osteoclastic bone
12
serum parathyroid
8
parathyroid hormone
8
hormone concentration
8
decreased day
8
bone
6
days
5
serum
5
effects mithramycin
4

Similar Publications

Yak milk inhibits osteoclast differentiation by suppressing TRPV5 expression.

J Dairy Sci

January 2025

Department of Food Science and Engineering, College of Life Science & Technology, Xinjiang University, Urumqi 830046, China; Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Xinjiang University, Urumqi 830046, China.

Yak milk is a potential nutrient for improving osteoporosis. However, the effect of yak milk on the expression of Caion channel TRPV5 during osteoclast (OC) differentiation is still unclear. This study used ruthenium red as a control to investigate the effect of yak milk on osteoclast differentiation and activity.

View Article and Find Full Text PDF

Our aim was to determine the effects of P intake on P balance, serum parathyroid hormone (PTH) levels and bone resorption during the final 4 weeks prepartum and the first 8 weeks of lactation. Sixty pregnant multiparous Holstein Friesian dairy cows were assigned to a randomized block design with repeated measurements and dietary treatments arranged according to a 2 × 2 factorial design. The experimental diets contained 3.

View Article and Find Full Text PDF

This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.

View Article and Find Full Text PDF

Objective: To evaluate the effects of tinidazole (TNZ) combined with minocycline (MINO) on therapeutic effectiveness, bone resorption, and inflammation in peri-implantitis (PI).

Methods: This retrospective study included 96 PI patients admitted between January 2023 and February 2024. Patients were divided into a control group (n = 46) treated with MINO and a research group (n = 50) treated with TNZ plus MINO.

View Article and Find Full Text PDF

Unlabelled: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers.

Purpose: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!